SCHEMBL3148206

SCHEMBL3148206

O=C(Nc1ccc(-c2csc(NC(=O)C3CCCN3C(=O)OCc3ccccc3)n2)cc1)C1CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
KDM4E B2RXH2 1/20 0.59
HSD17B10 Q99714 2/20 0.59
KDM1A O60341 1/20 0.58
RCOR1 Q9UKL0 1/20 0.58
NPSR1 Q6W5P4 1/20 0.56
TSHR P16473 3/20 0.56
ALDH1A1 P00352 3/20 0.56
KCNQ1 P51787 1/20 0.53
CTRB1 P17538 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
CNR2 P34972 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
GFER P55789 1/20 0.50
ENPP2 Q13822 3/20 0.49
TP53 P04637 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
USP2 O75604 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3144494 0.97 LMNA (0.59) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL13523985 0.92 KDM4E (0.60) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL3135595 0.92 KDM4E (0.60) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL13713000 0.92 KDM1A (0.58) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL3143756 0.92 KDM1A (0.58) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL3135634 0.92 LMNA (0.59) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL13524034 0.92 LMNA (0.59) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL3140343 0.91 KCNQ1 (0.58) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL13524070 0.91 KCNQ1 (0.58) LMNAKDM4EHSD17B10KDM1ARCOR1
SCHEMBL3139454 0.91 CNR2 (0.59) LMNAKDM4EHSD17B10KDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US claimed
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds SCHMITZ FRANZ ULRICH 2010-01-07 US disclosed
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds SCHMITZ FRANZ ULRICH 2010-01-07 US disclosed
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds SCHMITZ FRANZ ULRICH 2010-01-07 US disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
US-7595398-B2 N-(5-membered aromatic ring)-amido anti-viral compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-09-29 US disclosed
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US disclosed
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US disclosed
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004441-A1 N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds ZC3HAV1, ZC3HAV1L, HAVCR2 LMNA 1094/4885KDM4E 838/4885HSD17B10 4112/4885
US-20070265265-A1 N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS ZC3HAV1, ZC3HAV1L, HAVCR2 LMNA 1094/4885KDM4E 838/4885HSD17B10 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.